| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC2136 |
| Trial ID | NCT04007978 |
| Disease | B-Cell Lymphoma | Acute Lymphoblastic Leukemia |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Generation | 3rd |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies |
| Year | 2019 |
| Country | China |
| Company sponsor | Wuhan Union Hospital, China |
| Other ID(s) | WHUH-CART-CD22-01 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||
|
|||||||||